Claims
- 1. A piperidine compound selected from those having the formula I ##STR23## wherein R.sup.3 is 3,4-methylenedioxyphenyl, phenyl or naphthyl which are optionally substituted with one or more halogen, C.sub.1-6 -alkoxy, or phenoxy, cyano, mono or poly halogenated C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl, C.sub.1-16 -alkyl, or C.sub.3-5 -alkylene,
- R.sup.1 is C.sub.1-4 -alkyl substituted with, or C.sub.5-8 -alkyl unsubstituted or substituted with, one or more cyano, ethoxycarbonyl, dimethylamino, hydroxy, carbamoyl, C.sub.1-8 -alkoxy, or C.sub.3-8 cycloalkyl,
- X is hydrogen, halogen, trifluoromethyl, hydroxy, cyano, or C.sub.1-8 -alkoxy,
- Y is O or S;
- provided that R.sup.1 is not unsubstituted C.sub.1-8 -alkyl when R.sup.3 is 3,4-methylenedioxyphenyl, phenyl, or naphthyl optionally substituted with C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, or C.sub.3-5 -alkylene, and X is hydrogen or halogen,
- and pharmaceutically-acceptable acid addition salts thereof.
- 2. A compound of claim 1 wherein R.sup.3 is 3,4-methylenedioxyphenyl, optionally substituted with halogen or C.sub.1-6 -alkoxy, or phenyl substituted with C.sub.3-5 -alkylene.
- 3. A compound of claim 1 wherein X is hydrogen, halogen, trifluoromethyl or C.sub.1-6 -alkoxy.
- 4. A compound of claim 1 wherein R.sup.3 is 3,4-methylene dioxyphenyl, optionally substituted with halogen or C.sub.1-6 -alkoxy, or phenyl substituted with C.sub.3-5 -alkylene, and X is hydrogen, halogen, trifluoromethyl or C.sub.1-6 -alkoxy.
- 5. A compound of claim 1 which is (-)-trans-4-(4-methoxyphenyl)-3-(3,4-methylenedioxyphenoxymethyl)-1-pentylpiperidine oxalate.
- 6. A compound of claim 1 which is (+)-trans-4-(4-methoxyphenyl)-3-(3,4-methylenedioxyphenoxymethyl)-1-pentyl-piperidine oxalate.
- 7. A compound of claim 1 which is (+-)-trans-3-(3,4-methylenedioxyphenoxymethyl)-1-pentyl-4-(3-trifluoromethylphenyl)piperidine hydrochloride.
- 8. A compound of claim 1 which is (+)-trans-3-(2-bromo-4,5-methylenedioxyphenoxymethyl)-4-(4-fluorophenyl)-1-pentylpiperidine hydrochloride.
- 9. A compound of claim 1 which is (+-)-trans-3-(3,4-methylenedioxyphenoxymethyl)-1-pentyl-4(4-pentyloxyphenyl)piperidine hydrochloride.
- 10. A calcium channel inhibiting composition comprising an effective calcium uptake inhibitory amount of a compound of claim 1, together with a pharmaceutically-acceptable carrier or diluent.
- 11. A pharmaceutical composition according to claim 10 wherein it is in the form of an oral dosage unit containing 1-100 mg of the active compound.
Priority Claims (3)
Number |
Date |
Country |
Kind |
5232/86 |
Nov 1986 |
DKX |
|
3234/87 |
Jun 1987 |
DKX |
|
2310/88 |
Apr 1988 |
DKX |
|
Parent Case Info
The present application is a division of our prior-filed copending application, Ser. No. 337,301, filed Apr. 13, 1989, now U.S. Pat. No. 5,017,585, issued May 21, 1991, which in turn is a continuation-in-part of Ser. No. 106,154, filed Oct. 8, 1987, now U.S. Pat. No. 4,877,799, issued Oct. 31, 1989.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3912743 |
Christensen |
Oct 1975 |
|
5019582 |
Drejer |
May 1991 |
|
Non-Patent Literature Citations (1)
Entry |
Scarpelli et al. "Cell Injury" The Upjohn Co. Publisher, pp. 44-45 (1986). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
337301 |
Apr 1989 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
106154 |
Oct 1987 |
|